Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia

Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related... Adv Ther (2017) 34:2585–2600 DOI 10.1007/s12325-017-0624-6 ORIGINAL RESEARCH Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia . . . Adrian Skelly Hans-Joachim Carius Vladimir Bezlyak Fred K. Chen Received: May 3, 2017 / Published online: November 21, 2017 The Author(s) 2017. This article is an open access publication December 1, 2012, and March 31, 2015, with ABSTRACT follow-up of at least 6 months. The number of ranibizumab and aflibercept units dispensed Introduction: Anti-vascular endothelial growth was adjusted for baseline patient Medica- factor therapy is the standard of care for neo- tion-Based Disease Burden Index (MBDBI) vascular age-related macular degeneration scores. No difference in the number of ranibi- (nAMD). The dosage of two licensed agents, zumab versus aflibercept units dispensed was ranibizumab and aflibercept, was established concluded if the 95% confidence interval (CI) through clinical trials; however, it is unclear if limits of the adjusted mean difference between either agent is administered as recommended in the study cohorts were 1.00 unit or less. routine clinical practice. Using pharmacy claims Results: Baseline patient MBDBI scores were data, we investigated if the dispensing patterns similar for the ranibizumab (N = http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia

Loading next page...
 
/lp/springer_journal/dispensing-patterns-of-ranibizumab-and-aflibercept-for-the-treatment-2YHU1aIZEe
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0624-6
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2017) 34:2585–2600 DOI 10.1007/s12325-017-0624-6 ORIGINAL RESEARCH Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia . . . Adrian Skelly Hans-Joachim Carius Vladimir Bezlyak Fred K. Chen Received: May 3, 2017 / Published online: November 21, 2017 The Author(s) 2017. This article is an open access publication December 1, 2012, and March 31, 2015, with ABSTRACT follow-up of at least 6 months. The number of ranibizumab and aflibercept units dispensed Introduction: Anti-vascular endothelial growth was adjusted for baseline patient Medica- factor therapy is the standard of care for neo- tion-Based Disease Burden Index (MBDBI) vascular age-related macular degeneration scores. No difference in the number of ranibi- (nAMD). The dosage of two licensed agents, zumab versus aflibercept units dispensed was ranibizumab and aflibercept, was established concluded if the 95% confidence interval (CI) through clinical trials; however, it is unclear if limits of the adjusted mean difference between either agent is administered as recommended in the study cohorts were 1.00 unit or less. routine clinical practice. Using pharmacy claims Results: Baseline patient MBDBI scores were data, we investigated if the dispensing patterns similar for the ranibizumab (N =

Journal

Advances in TherapySpringer Journals

Published: Nov 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off